Seek Returns

ROIV vs. WAT: Roivant Sciences vs. Waters Stock Comparison

How do Roivant Sciences (ROIV) and Waters (WAT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Roivant Sciences (ROIV) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ROIV is classified in Biotechnology while WAT is classified in Life Sciences Tools & Services.

Waters (WAT) has more than two decades of public-market history since November 17, 1995, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.

Company profile comparison for Roivant Sciences (ROIV) and Waters (WAT)
Profile ItemROIVWAT
NameRoivant Sciences Ltd.Waters Corporation
Country/RegionUnited KingdomUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization28.08 billion USD44.93 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateDecember 8, 2020November 17, 1995
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ROIV
WAT
GSPC
Loading price history…
Roivant Sciences (ROIV) vs. Waters (WAT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Roivant Sciences (ROIV) and Waters (WAT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Roivant Sciences (ROIV) and Waters (WAT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Roivant Sciences (ROIV) and Waters (WAT)
MetricROIVWAT
Total Return (1Y)96.75%27.70%
Total Return (3Y, Annualized)68.04%23.32%
Total Return (5Y, Annualized)36.73%6.27%

Risk Profile

Drawdown History

ROIV
WAT
GSPC
Loading price history…
Roivant Sciences (ROIV) vs. Waters (WAT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Roivant Sciences (ROIV) and Waters (WAT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Roivant Sciences (ROIV) and Waters (WAT)
MetricROIVWAT
Volatility (1Y, Annualized)47.99%35.45%
Beta (5Y)1.171.13
Max Drawdown (5Y)-79.22%-36.47%
Avg. Volume (3M)7.82M816.72K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ROIV and WAT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Roivant Sciences (ROIV) and Waters (WAT)
MetricROIVWAT
Sharpe Ratio (1Y)1.930.66
Sortino Ratio (1Y)4.030.98

Profitability

ROE (TTM)

Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Waters (WAT) reports 1.12%, ranking against industry peers normally.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max
109.18%
Q3
6.23%
ROIV
-8.52%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12%

Max
109.18%
Q3
6.23%
WAT
1.12%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Roivant Sciences (ROIV) at 0.00% and Waters (WAT) at 1.76% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
ROIV
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.76%

Max
18.05%
Q3
4.78%
WAT
1.76%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Waters (WAT) reports 11.38%, ranking against industry peers normally.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
ROIV
-25,408.11%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.38%

Max
83.12%
Q3
14.77%
WAT
11.38%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Roivant Sciences (ROIV) and Waters (WAT)
MetricROIVWAT
ROE (TTM)-8.52%1.12%
ROA (TTM)-16.28%2.36%
Net Margin (TTM)0.00%1.76%
Operating Margin (TTM)-25,408.11%11.38%
Gross Margin (TTM)0.00%49.83%

Growth

Revenue Growth

Waters (WAT) at 6.99% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Waters (WAT) reports EPS growth of 0.47%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.

Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Roivant Sciences (ROIV) and Waters (WAT)
MetricROIVWAT
Revenue Growth (YoY)-71.57%6.99%
Revenue Growth (3Y CAGR)-36.01%2.12%
EPS Growth (YoY)--0.47%
EPS Growth (3Y CAGR)---2.84%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Roivant Sciences (ROIV) shows current ratio of 16.72 against its industry benchmark, while Waters (WAT) has no reading this period.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max
25.13
ROIV
16.72
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
WAT
--
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): WAT does not report current ratio, so it has no value marker; ROIV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

Both Roivant Sciences (ROIV) at 0.02 and Waters (WAT) at 0.34 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max
1.42
Q3
0.65
Median
0.15
ROIV
0.02
Q1
0.02
Min
0.00

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.34

Max
1.42
Q3
0.65
WAT
0.34
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Roivant Sciences (ROIV) and Waters (WAT)
MetricROIVWAT
Current Ratio (MRQ)16.72--
Debt / Equity (MRQ)0.020.34
Net Debt / EBITDA--3.23

Dividends

Dividend Yield (TTM)

Neither Roivant Sciences (ROIV) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

WAT
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Roivant Sciences (ROIV) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

WAT
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Roivant Sciences (ROIV) and Waters (WAT)
MetricROIVWAT
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Waters (WAT) trades at 191.46 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
ROIV
--

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

191.46

WAT
191.46
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): ROIV does not report P/E ratio, so it has no value marker; WAT is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Waters (WAT) at 8.01 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV
3,728.61
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.01

Max
58.18
Q3
25.77
WAT
8.01
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Waters (WAT) at 2.94 is valued about in line with its industry on P/B ratio, while Roivant Sciences (ROIV) at 6.64 carries an above-peer premium to book — ROIV is pricier on assets.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max
13.53
ROIV
6.64
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.94

Max
13.53
Q3
6.54
Median
3.25
WAT
2.94
Q1
1.69
Min
-5.59
Loading chart…
Roivant Sciences (ROIV) vs. Waters (WAT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Roivant Sciences (ROIV) and Waters (WAT)
MetricROIVWAT
P/E Ratio (TTM)--191.46
P/S Ratio (TTM)3,728.618.01
P/B Ratio (MRQ)6.642.94
Free Cash Flow Yield (TTM)-3.98%--